PAKing up to the endothelium

Angiogenesis recapitulates the growth of blood vessels that progressively expand and remodel into a highly organized and stereotyped vascular network. During adulthood, endothelial cells that formed the vascular wall retain their plasticity and can be engaged in neo-vascularization in response to physiological stimuli, such as hypoxia, wound healing and tissue repair, ovarian cycle and pregnancy. In addition, numerous human diseases and pathological conditions are characterized by an excessive, uncontrolled and aberrant angiogenesis. The signalling pathways involving the small Rho GTPase, Rac and its downstream effector the p21-activated serine/threonine kinase (PAK) had recently emerged as pleiotropic modulators in these processes. Indeed, Rac and PAK were found to modulate endothelial cell biology, such as sprouting, migration, polarity, proliferation, lumen formation, and maturation. Elucidating the Rac/PAK molecular circuitry will provide essential information for the development of new therapeutic agents designed to normalize the blood vasculature in human diseases.

💡 Research Summary

Angiogenesis, the process by which new blood vessels sprout, elongate, and remodel into a highly ordered vascular network, is driven by a tightly regulated cascade of signaling events. In adult organisms, endothelial cells (ECs) retain a remarkable degree of plasticity, enabling them to respond to physiological cues such as hypoxia, wound repair, the ovarian cycle, and pregnancy. Conversely, many pathological conditions—including cancer, diabetic retinopathy, and chronic inflammatory diseases—are characterized by excessive, uncontrolled angiogenesis that fuels disease progression. Understanding the molecular circuitry that governs both normal and pathological vascular growth is therefore a central goal of vascular biology and therapeutic development.

Recent work has highlighted the small Rho GTPase Rac and its downstream effector, the p21‑activated kinase (PAK), as pivotal modulators of endothelial behavior. Rac cycles between an inactive GDP‑bound state and an active GTP‑bound state, where it engages multiple effectors. Among these, PAK family members (group I: PAK1‑3; group II: PAK4‑6) act as serine/threonine kinases that integrate Rac signals with other pathways to control cytoskeletal dynamics, cell polarity, proliferation, and survival.

Mechanistic Overview
When Rac‑GTP binds to the CRIB domain of PAK, the kinase undergoes a conformational change that enables autophosphorylation at key activation loops (e.g., Thr423 in PAK1). This activation is further reinforced by upstream kinases such as Src and PI3K. Active PAK phosphorylates a suite of substrates:

• LIM kinase (LIMK) and cofilin – regulating actin filament turnover, thereby promoting filopodia and lamellipodia formation essential for sprouting.
• Myosin light chain kinase (MLCK) and myosin light chain (MLC) – modulating contractility, which is critical for lumen formation and tube stabilization.
• Par‑3/Par‑6/aPKC complex – directing apico‑basal polarity, ensuring that newly formed vessels acquire proper orientation and barrier function.

Through these actions, Rac/PAK coordinates the early migratory phase of angiogenesis, the establishment of endothelial polarity, and the later maturation steps that involve lumen expansion and pericyte recruitment.

Cross‑Talk with Other Angiogenic Pathways
PAK does not act in isolation. It forms positive feedback loops with VEGF‑R2 signaling, amplifying downstream Akt and ERK activation, which drives endothelial proliferation and survival. Moreover, PAK interacts with focal adhesion kinase (FAK) and Src, facilitating dynamic turnover of focal adhesions that allow cells to detach and re‑attach as they migrate. Importantly, PAK can suppress RhoA/ROCK activity, tempering excessive contractility that would otherwise impede tube formation.

Pathological Angiogenesis
In tumor microenvironments, chronic inflammation, or hyperglycemic retina, Rac/PAK signaling becomes hyper‑activated. Elevated VEGF levels, oxidative stress, and inflammatory cytokines maintain Rac in its GTP‑bound state, leading to sustained PAK activity. This hyper‑activation fuels aberrant sprouting, chaotic vessel architecture, and increased permeability—all hallmarks of disease‑associated angiogenesis. Pre‑clinical models using small‑molecule PAK inhibitors such as FRAX597, IPA‑3, or more selective ATP‑competitive compounds have demonstrated reduced neovascularization, tumor growth arrest, and normalization of vascular permeability.

Therapeutic Opportunities and Challenges
Targeting PAK presents a compelling strategy, yet several hurdles remain:

1. Selectivity – PAK isoforms have overlapping yet distinct functions; pan‑PAK inhibition can disrupt normal vascular homeostasis and cause off‑target effects in other tissues.
2. Delivery – Systemic inhibition risks toxicity; therefore, nanoparticle‑based delivery, antibody‑drug conjugates, or endothelial‑specific promoters are being explored to achieve tissue‑restricted blockade.
3. Feedback Compensation – Inhibition of PAK can trigger compensatory activation of parallel Rho GTPases (e.g., Cdc42) or up‑regulation of VEGF, necessitating combination therapies.

Future research should focus on:

• Structural biology to design allosteric inhibitors that lock PAK in an inactive conformation without affecting ATP binding.
• Single‑cell omics to map Rac/PAK activity across endothelial subpopulations during distinct angiogenic stages.
• Biomarker development – phospho‑PAK levels in plasma or tissue could stratify patients likely to benefit from PAK‑targeted therapy.
• Organoid and iPSC‑derived vascular models for high‑throughput screening of candidate compounds and assessment of vascular normalization.

Conclusion
The Rac/PAK axis operates as a central hub that integrates extracellular angiogenic cues with intracellular cytoskeletal and polarity programs. By orchestrating endothelial sprouting, migration, lumen formation, and maturation, this pathway underlies both physiological vascular remodeling and the pathological neovascularization seen in numerous diseases. A nuanced understanding of Rac/PAK signaling—its isoform‑specific functions, cross‑talk with VEGF, PI3K/Akt, MAPK, and RhoA/ROCK pathways, and context‑dependent regulation—will be essential for the rational design of next‑generation anti‑angiogenic therapies aimed at normalizing, rather than merely ablating, the vasculature.